Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
2.7
2.0
Journals
Children
Special Issues
Pediatric Inflammatory Bowel Disease: Diagnosis and Treatment
share announcement

Pediatric Inflammatory Bowel Disease: Diagnosis and Treatment

A special issue of Children (ISSN 2227-9067). This special issue belongs to the section "Pediatric Gastroenterology and Nutrition".

Deadline for manuscript submissions: closed (15 December 2024) | Viewed by 2568

Special Issue Editor

Dr. Claudia Banzato

E-Mail Website
Guest Editor
Pediatric Unit, Department of Surgical Sciences, Dentistry, Gynecology and Pediatrics, University of Verona, Verona, Italy
Interests: eosinophilc oesophagitis; inflammatory bowel disease; celiac disease

Special Issue Information

Dear Colleagues,

Inflammatory bowel disease (IBD) is one of the most interesting topics of treatment and research for gastroenterologists. The incidence of IBD has been constantly increasing in the last few years, particularly in children. Furthermore, the complexity of IBD is a particular challenge in the pediatric population, usually affected by more severe symptoms.

In some cases, the diagnosis is easy and quick, but most of the time, the diagnostic approach is very complex, and gastroenterologists need a solid scientific background as well as a bit of intuition.

The treatment of patients with IBD is an important task for pediatric gastroenterologists. There are several approaches to IBD treatment, including specific diet modulation of the microbiome, immune modulators, biologic drugs, new biologics, and surgery.

A combination of biological agents, drugs, and diet is an interesting possibility for the most severe disease, especially in pediatrics, where approved drugs are very limited.

Dr. Claudia Banzato
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Children is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • inflammatory bowel disease
  • biological agents
  • nutritional therapy
  • children
  • severe disease

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

12 pages, 464 KiB  
Article
Dual Biologic or Small Molecule Therapy in Pediatric Inflammatory Bowel Disease: A Single Center Experience
by Cheng Guo, Jin Zhou, Guoli Wang and Jie Wu
Children 2025, 12(1), 75; https://doi.org/10.3390/children12010075 - 9 Jan 2025
Viewed by 971
Abstract
Purpose: Currently, there is no clinical data reported on the therapy of dual biological agents in pediatric-onset inflammatory bowel disease (PIBD) patients in China. The purpose of this study was to evaluate the efficacy and safety of dual biologic therapy or biologics combined [...] Read more.
Purpose: Currently, there is no clinical data reported on the therapy of dual biological agents in pediatric-onset inflammatory bowel disease (PIBD) patients in China. The purpose of this study was to evaluate the efficacy and safety of dual biologic therapy or biologics combined with small molecule drugs in refractory PIBD patients in China. Methods: Clinical, laboratory, endoscopic, and ultrasound data of PIBD patients from the Department of Gastroenterology of Beijing Children’s Hospital between January 2021 and October 2024 were retrospectively analyzed. PIBD patients who received dual biologic treatment or a combination of biologic and small molecule therapy were included in this study. Steroid-free clinical remission and adverse events were recorded. Results: In this retrospective study, out of 520 children with IBD, twelve children (2.3%) were diagnosed with refractory PIBD and met the criteria for dual biotherapy, including four with UC (33%) and eight with CD (67%). The median age of patients was 13.64 (range, 1.2–17.1) years at eligibility for dual biologic therapy. There are eight (67%) patients treated with infliximab/ustekinumab (IFX + UST), three (25%) patients with upadacitinib/ustekinumab (UPA + UST), one (8%) patient with infliximab/vedolizumab (IFX + VDZ). At 3, 6, and 12 months of dual biological treatment, 91.2% (11/12), 100% (12/12), and 100% (12/12) patients showed steroid-free clinical remission, respectively. The median fecal calprotectin decreased significantly from 1852.5 µg/g (IQR, 762.5–1988.25) at baseline to 359.0 (IQR, 217.5–730.25) μg/g at 3 months, 113 (IQR, 73.7–256) μg/g at 6 months, and 82.5 (IQR, 40.25–122.25) μg/g at 12 months. Only one CD patient with IFX + UST reported mild elevation of aminotransferase, who recovered after symptomatic treatment. Conclusions: Dual biologic or small molecule therapy may be effective and safe for children with refractory PIBD in China. Full article
(This article belongs to the Special Issue Pediatric Inflammatory Bowel Disease: Diagnosis and Treatment)
►▼ Show Figures

Figure 1

12 pages, 1269 KiB  
Article
Evaluation of Growth in Children with Inflammatory Bowel Disease
by Uğur Altaş and Deniz Ertem
Children 2024, 11(9), 1038; https://doi.org/10.3390/children11091038 - 25 Aug 2024
Viewed by 1204
Abstract
Objective: This study aimed to evaluate changes in growth parameters in children diagnosed with inflammatory bowel disease (IBD). Methods: The data of children with IBD between 2010 and 2018 were retrospectively reviewed. Anthropometric measurements (height, weight, and BMI [body mass index]), and clinical [...] Read more.
Objective: This study aimed to evaluate changes in growth parameters in children diagnosed with inflammatory bowel disease (IBD). Methods: The data of children with IBD between 2010 and 2018 were retrospectively reviewed. Anthropometric measurements (height, weight, and BMI [body mass index]), and clinical and laboratory data were evaluated at diagnosis and follow-up (1st and 2nd year). Patients’ growth was assessed by calculating weight-for-age, height-for-age, BMI-for-age, and growth velocity z-scores. Results: Thirty-six patients (46.2%) had Crohn’s disease (CD), and 42 (53.8%) had ulcerative colitis (UC). Weight-for-age, height-for-age, and BMI-for-age z-scores significantly increased over the follow-up period in the CD patients (p < 0.05). Growth velocity z-scores were also significantly higher in the second year compared to the first year in the CD patients (p < 0.001). Improvements in weight-for-age, height-for-age, and BMI-for-age z-scores were not significant over the two-year follow-up in the UC patients (p > 0.05). Growth velocity z-scores in the UC patients were higher in the second year compared to the first year, but this difference was not significant (p = 0.115). Conclusions: The growth parameters showed improvement after a two-year follow-up. Regular anthropometric measurements, along with clinical and laboratory markers, should be used to monitor treatment response, which can help achieve optimal growth in children with IBD. Full article
(This article belongs to the Special Issue Pediatric Inflammatory Bowel Disease: Diagnosis and Treatment)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop